These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 17987222)

  • 1. Nilotinib therapy in chronic myelogenous leukemia.
    Quintas-Cardama A; Cortes J
    Drugs Today (Barc); 2007 Oct; 43(10):691-702. PubMed ID: 17987222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.
    Quintás-Cardama A; Cortes J
    Future Oncol; 2008 Oct; 4(5):611-21. PubMed ID: 18922118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
    Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
    Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
    Fullmer A; Kantarjian H; Cortes J; Jabbour E
    Expert Opin Pharmacother; 2010 Dec; 11(18):3065-72. PubMed ID: 21073351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
    Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H
    IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
    Hazarika M; Jiang X; Liu Q; Lee SL; Ramchandani R; Garnett C; Orr MS; Sridhara R; Booth B; Leighton JK; Timmer W; Harapanhalli R; Dagher R; Justice R; Pazdur R
    Clin Cancer Res; 2008 Sep; 14(17):5325-31. PubMed ID: 18765523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy options in imatinib failures.
    Ramirez P; DiPersio JF
    Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
    von Bubnoff N; Manley PW; Mestan J; Sanger J; Peschel C; Duyster J
    Blood; 2006 Aug; 108(4):1328-33. PubMed ID: 16614241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.
    Breccia M; Alimena G
    Curr Drug Targets; 2009 Jun; 10(6):530-6. PubMed ID: 19519355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
    Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
    J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted drugs in chronic myeloid leukemia.
    Gora-Tybor J; Robak T
    Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
    Maekawa T; Ashihara E; Kimura S
    Int J Clin Oncol; 2007 Oct; 12(5):327-40. PubMed ID: 17929114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
    Jiang H; Chen SS; Jiang B; Jiang Q; Qin YZ; Lai YY; Liu YR; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):123-6. PubMed ID: 22730663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
    DeAngelo DJ; Attar EC
    Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nilotinib for the treatment of chronic myeloid leukemia.
    Kim TD; Dörken B; le Coutre P
    Expert Rev Hematol; 2008 Oct; 1(1):29-39. PubMed ID: 21083005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
    Erba HP; Pham DC; Zaiden R; Vu H; Tai S
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.
    Bauer RC; Sänger J; Peschel C; Duyster J; von Bubnoff N
    Clin Cancer Res; 2013 Jun; 19(11):2962-72. PubMed ID: 23549879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.